Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ocrelizumab, and Interferon beta-1a

被引：0
|
作者：
Hersh, Carrie [1 ]
Aladro-Benito, Yolanda [2 ]
Lewin, James B. [3 ]
Shen, Changyu [3 ]
Bozin, Ivan [4 ]
Sun, Zhaonan [3 ]
机构：
[1] Cleveland Clin, Clin Lou Ruvo Ctr Brain Hlth Las Vegas, Las Vegas, NV USA
[2] Hosp Univ Getafe, Madrid, Spain
[3] Biogen, Cambridge, MA USA
[4] Biogen, Baar, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P831/1806
引用
收藏
页码：641 / 641
页数：1
相关论文
共 50 条
  • [1] Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ozanimod, and Interferon beta-1a for Relapsing MS
    Jiang, T.
    Bozin, I.
    Lewin, J.
    Shen, C.
    Soderbarg, K.
    Arnold, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 421 - 421
  • [2] Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
    Jiang, Tammy
    Shanmugasundaram, Mathura
    Bozin, Ivan
    Freedman, Mark S.
    Lewin, James B.
    Shen, Changyu
    Ziemssen, Tjalf
    Arnold, Douglas L.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (10)
  • [3] Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis
    Tammy Jiang
    Tjalf Ziemssen
    Sibyl Wray
    Changyu Shen
    Karin Söderbärg
    James B. Lewin
    Ivan Božin
    Mark S. Freedman
    CNS Drugs, 2023, 37 : 441 - 452
  • [4] Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis
    Jiang, Tammy
    Ziemssen, Tjalf
    Wray, Sibyl
    Shen, Changyu
    Soderbarg, Karin
    Lewin, James B.
    Bozin, Ivan
    Freedman, Mark S.
    CNS DRUGS, 2023, 37 (05) : 441 - 452
  • [5] Matching-adjusted indirect comparisons of diroximel fumarate, ponesimod, and teriflunomide for relapsing multiple sclerosis
    Jiang, T.
    Shen, C.
    Soderbarg, K.
    Lewin, J. B.
    Bozin, I.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 623 - 623
  • [6] Adis summary of research: Matching-adjusted indirect comparisons of diroximel fumarate, ponesimod, and teriflunomide for relapsing multiple sclerosis
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, 40 (07) : 239 - 240
  • [7] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    You, Xiaojun
    Scott, Thomas
    Shang, Shulian
    Evilevitch, Vladimir
    Sabetella, Guido
    Werneburg, Brian
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 415 - 415
  • [8] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    Scott, Thomas
    Shang, Shulian
    Castrillo-Viguera, Carmen
    NEUROLOGY, 2017, 88
  • [9] A Matching-Adjusted Indirect C\omparison of Ozanimod to Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
    McGinley, M.
    Paul, D.
    Branchcomb, T.
    Arndorfer, S.
    Navickas, C.
    Gupte-Singh, K.
    Kantor, D.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 39 - 39
  • [10] Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
    Coyle, Patricia K.
    Shang, Shulian
    Xiao, Zhen
    Dong, Qunming
    Castrillo-Viguera, Carmen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 22 : 134 - 138
12345